



Docket No.: 62146(71526)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Robert Ramage et al.

Application No.: 10/517,803

Confirmation No.: 8946

Filed: December 10, 2004

Art Unit: N/A

For: PAR-2-ACTIVATING PEPTIDE
DERIVATIVE AND PHARMACEUTICAL
COMPOSITION USING THE SAME

Examiner: Not Yet Assigned

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

MS Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated August 2, 2007 (copy attached). Applicant hereby submits its response within the two-month response period set to expire on October 2, 2007.

Submitted herewith in connection with the above-referenced patent application is a computer readable copy of the Sequence Listing, paper copy of the Sequence Listing, Statement in support of the submission, and Preliminary Amendment. No new matter has been added to the substitute Sequence Listing.

Applicant respectfully requests the above-referenced patent application be placed upon the files for examination.

Application No.: 10/517,803

2

Docket No.: 62146(71526)

Dated: October 2, 2007

Respectfully submitted,

By Christine C. O'Day

Christine C. O'Day

Registration No.: 38,256

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5558

Attorneys/Agents For Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/517,803	Robert Ramage	62146(71526)

21874
 EDWARDS ANGELL PALMER & DODGE LLP
 P.O. BOX 55874
 BOSTON, MA 02205



INTERNATIONAL APPLICATION NO.	
PCT/JP03/07333	
I.A. FILING DATE	PRIORITY DATE
06/10/2003	06/10/2002

CONFIRMATION NO. 8946
 371 WITHDRAWAL NOTICE



OC000000017996124

Date Mailed: 08/02/2007

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Notice mailed on 05/23/2005 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the enclosed Notice. We apologize for any inconvenience this caused.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/517,803	Robert Ramage	62146(71526)

21874

EDWARDS ANGELL PALMER & DODGE LLP
 P.O. BOX 55874
 BOSTON, MA 02205



INTERNATIONAL APPLICATION NO.

PCT/JP03/07333

I.A. FILING DATE

06/10/2003

PRIORITY DATE

06/10/2002

CONFIRMATION NO. 8946

371 FORMALITIES LETTER



OC000000025170788

Date Mailed: 08/02/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-

3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.

- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/517,803	PCT/JP03/07333	62146(71526)

FORM PCT/DO/EO/922 (371 Formalities Notice)



Application No. (if known): 10/517,803

Attorney Docket No.: 62146(71526)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM054389439US in an envelope addressed to:

MS Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 2, 2007
Date

Signature

Lynn Marcus

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 239-0100
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Response to Notice to Comply with Requirements for Nucleotide or Amino Acid Sequence Disclosure (2 pages)
Copy of Notice to Comply with Requirements for Nucleotide or Amino Acid Sequence Disclosure (4 pages)
Amendment in Response to Notice Under 37 CFR 1.821-825 (8 pages)
Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-825 (1 page)
Paper Copy of Sequence Listing (3 pages)
Computer Readable Sequence Listing - CD